Biologics

Reinvent Biologics is a regenerative medicine company.

Platelet-rich plasma injections and stem cell therapies are ushering in a "new dawn" in orthopedics, according to Jason Arora, DO, a board-certified interventional spine and pain management physician at West Orange, N.J.-based Atlantic Spine Center.

Cynata Therapeutics entered into a licensing agreement with Fujifilm Holdings to begin stem cell therapy clinical trials in the U.S. and Japan, according to Nikkei Asian Review.

New York City-based Hospital for Special Surgery researchers launched a clinical trial to assess the effects of Organogenesis' ReNu on knee function.

A stem cell provider registry program will improve the quality of treatments, wrote Fabio Rossi, MD, PhD, and Judy Illes, PhD, in an op-ed in the Vancouver Sun.

Baxter International received FDA 510(k) clearance for its Altapore Bioactive Bone Graft for spinal fusion.

Minneapolis-based University of Minnesota Medical School researchers are using 3D technology to identify skeletal muscle stem cells for transplantation, according to Health Data Management.

Female ankylosing spondylitis patients do not respond as well to biologic treatment as their male counterparts, according to a study presented at the International Congress on Spondyloarthritides 2018 in Gent, Belgium, Oct. 4-8, and reported in Medscape.

Natesh Parashurama, MD, PhD, is a former surgeon and current stem cell researcher. Dr. Parashurama is an assistant chemical and biological engineering professor at the University of Buffalo (N.Y.), where he builds 3D internal organs from human stem cells.

Dallas-based University of Texas Southwestern Medical Center researchers are developing a stem cell-based treatment for a rare spinal cord disorder.